Literature DB >> 2377664

Haloperidol prevents the reinstatement of amphetamine-rewarded runway responding in rats.

A Ettenberg1.   

Abstract

Animals were trained to traverse a straight-alley once each day for a reward of 1.0 mg/kg SC d-amphetamine sulfate. After 14 days of acquisition, extinction trials were initiated in which the amphetamine reward was replaced by injections of physiological saline. After running speeds had decreased to less than one third those of preextinction values, rats received a single amphetamine-rewarded trial either in the absence or presence of haloperidol (0.075, 0.15 or 0.3 mg/kg IP). Twenty-four hours later, animals were tested for reinstatement of operant running in a single drug-free Test trial. Animals that were nondrugged during the amphetamine-rewarded trial demonstrated a statistically reliable increase in running speed on the Test trial relative to extinction baseline speeds. In contrast, animals that were under the influence of medium or high doses of haloperidol during the amphetamine-rewarded trial failed to show Test day increases in running speed. This result did not stem from some residual sedative or performance impairing quality of the drug since a "motor control group" administered a high dose of haloperidol shortly after a rewarded trial, was able to demonstrate unimpaired reinstatement of operant running on Test day (i.e., 24 hr later). These findings support the view that dopamine systems play a role in the neural substrates underlying the incentive motivational properties of amphetamine reinforcement.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2377664     DOI: 10.1016/0091-3057(90)90268-m

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  14 in total

1.  Animal model for investigating the anxiogenic effects of self-administered cocaine.

Authors:  A Ettenberg; T D Geist
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Neuronal substrates of relapse to cocaine-seeking behavior: role of prefrontal cortex.

Authors:  George V Rebec; WenLin Sun
Journal:  J Exp Anal Behav       Date:  2005-11       Impact factor: 2.468

3.  Morphine-conditioned single-trial place preference: role of nucleus accumbens shell dopamine receptors in acquisition, but not expression.

Authors:  Sandro Fenu; Liliana Spina; Emilia Rivas; Rosanna Longoni; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2006-05-25       Impact factor: 4.530

4.  Drug-motivated behavior in rats with lesions of the thalamic orosensory area.

Authors:  Jennifer E Nyland; Danielle N Alexander; Patricia S Grigson
Journal:  Behav Neurosci       Date:  2015-12-14       Impact factor: 1.912

5.  Nicotine-conditioned single-trial place preference: selective role of nucleus accumbens shell dopamine D1 receptors in acquisition.

Authors:  Liliana Spina; Sandro Fenu; Rosanna Longoni; Emilia Rivas; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2005-12-10       Impact factor: 4.530

Review 6.  Modeling relapse in animals.

Authors:  Rémi Martin-Fardon; Friedbert Weiss
Journal:  Curr Top Behav Neurosci       Date:  2013

7.  Effects of haloperidol in a response-reinstatement model of heroin relapse.

Authors:  A Ettenberg; L A MacConell; T D Geist
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

8.  Heightened drug-seeking motivation following extended daily access to self-administered cocaine.

Authors:  Osnat Ben-Shahar; Eric J Posthumus; Stephanie A Waldroup; Aaron Ettenberg
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-01-11       Impact factor: 5.067

9.  Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats.

Authors:  Keith L Shelton; Elizabeth S Hendrick; Patrick M Beardsley
Journal:  Drug Alcohol Depend       Date:  2013-01-29       Impact factor: 4.492

Review 10.  The runway model of drug self-administration.

Authors:  Aaron Ettenberg
Journal:  Pharmacol Biochem Behav       Date:  2008-11-13       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.